Zealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is Pricey

2025-05-16 16:24:43 ET

Summary

• Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide.
• Petrelintide, an amylin analog, could rival current market leaders if clinical data proves best-in-class efficacy and tolerability, but success is not guaranteed.
• Survodutide and other pipeline assets offer upside, but competitive pressure and high expectations create significant volatility and risk for Zealand shares.
• Given the current data and competitive landscape, I am staying on the sidelines and not buying ZLDPF stock until further clinical results are available.

Investment Overview

Zealand Pharma A/S ( OTCPK:ZLDPF ), founded in 1997 and headquartered in Soborg, Denmark, is one of the more advanced players in the emerging obesity treatment market, estimated by some to be worth >$200bn by 2031, with 16 new drugs on the market....

Read the full article on Seeking Alpha

For further details see: